FDA Approves Ryzumvi Eye Drops for Presbyopia, Adding a Drug Option to the Reading Glasses Habit
The U.S. Food and Drug Administration on October 16 approved Ryzumvi, a prescription eye drop, to treat presbyopia in adults, making it the second approved use for a medicine already on pharmacy shelves. The Ryzumvi presbyopia approval gives the roughly nine in ten Americans over 45 who struggle to focus on near objects a pharmacologic option that companies pitch as working alongside, not instead of, reading glasses. For patients, the question is practical: how well does it work, what are the side effects, and when will it be available.
Key Takeaways:
- – The FDA approved a supplemental new drug application for phentolamine ophthalmic solution 0.75 percent, marketed as Ryzumvi, for presbyopia in adults on October 16, 2026.
- – Approval rests on the Phase 3 VEGA-2 and VEGA-3 trials, which met their primary and all key secondary efficacy endpoints with no treatment-related serious adverse events reported.
- – The most common side effects in the presbyopia studies were conjunctival hyperemia, or eye redness, at 21 percent, and irritation at the application site at 16 percent.
- – Presbyopia affects about 90 percent of U.S. adults over 45; Ryzumvi is already approved for reversing dilation after eye exams.
What Changed in the Label
Ryzumvi has been on the U.S. market since 2023 for reversing mydriasis, the pupil dilation produced by the drops ophthalmologists use during eye exams. The new supplemental approval expands the indication list to include presbyopia in adults, an age-related condition in which the eye’s lens loses flexibility and near focus blurs, typically beginning in the early to mid-40s. Opus Genetics, which develops the molecule, announced the approval, and Viatris holds exclusive U.S. rights through a licensing agreement; the approval triggers a milestone payment to Opus.
That dual indication is why the approval moved fast by drug-development standards. The safety database and manufacturing pathway already existed from three years of dilated-eye-exam reversals, so the FDA only needed new efficacy data, which came from the dedicated presbyopia trial program rather than a from-scratch development effort.
How the Drop Works
Phentolamine is a nonselective alpha-1 and alpha-2 adrenergic antagonist applied as a topical drop. It reduces pupil diameter by blocking alpha-1 receptors on the iris dilator muscle, creating a mild, temporary constriction that increases depth of focus. That mechanism is central to how the drug is positioned: it acts through the pupil rather than through the ciliary muscle, which is the part of the eye that ages in presbyopia, so the drop does not attempt to restore lost flexibility.
The formulation is preservative-free, designed to improve near vision while leaving distance vision intact, an engineering goal that distinguishes it from earlier drops in this class that narrowed the pupil so aggressively that some patients reported dimness or driving-vision complaints at night. The company is also studying the same drug in a Phase 3 program for dim-light vision disturbances after refractive surgery, which will test how the molecule performs in low-light conditions, exactly the scenario where pupil constriction could cut both ways.
What the Trials Showed
The approval is supported by the pivotal Phase 3 VEGA-2 and VEGA-3 trials, both of which met their primary endpoints and all key secondary efficacy endpoints, with no treatment-related serious adverse events reported. In the presbyopia studies, the most common ocular adverse reactions above 5 percent were conjunctival hyperemia at 21 percent and instillation site irritation at 16 percent; the majority of adverse reactions across the program were described as mild, transient and self-resolving.
For patients, efficacy endpoints changing from a binary need for glasses to reading improvement means relatively modest single-digit line gains on reading charts, delivered within about an hour of dosing and lasting for a dosing day, which is why the indication is framed as on-demand use rather than a permanent correction. The practical reading: expect a drop that takes the edge off restaurant menus and phone screens for hours at a time, not one that retires your reading glasses permanently.
Who Should and Should Not Use It
The approval is for adults with presbyopia, and the labeling carries specific cautions. Ryzumvi is not recommended in patients with active ocular inflammation such as iritis. Contact lens wearers should remove lenses before instilling the drops and wait ten minutes after dosing before reinsertion. Patients should avoid touching the vial tip to the eye or any surface to prevent contamination and injury. Anyone considering it should review their full medication history with an eye-care provider, since alpha-blockers and other cardiovascular drugs can interact with systemic absorption, and the prescriber is the right person to weigh dim-light driving against near-work benefits.
Availability timing is the next open question: Viatris has said it is exploring a U.S. commercialization partner for the presbyopia indication, and the company has not announced a U.S. launch date or pricing. Existing Ryzumvi supply for exam-reversal use does not automatically translate to retail availability for daily presbyopia dosing until commercial logistics are settled.
Context: The Presbyopia Drop Race
Ryzumvi enters a market where a predecessor category opened the door and stumbled commercially. The first approved presbyopia drop, pilocarpine-based, launched in late 2021 with strong trial data but mixed real-world reception and a price point above what many patients would pay to delay reading glasses. The class challenges are known: effects are temporary, dimmer vision at night bothers some drivers, and adherence falls when a daily cosmetic-level benefit costs a pharmacy copay.
Ryzumvi’s differentiation is mechanistic, acting through the dilator muscle rather than the ciliary body, and its existing approval gives it a cost and regulatory head start. Whether patients adopt it depends less on trial lines than on the everyday question the earlier entrant could not fully answer: is clearer phone reading worth a daily drop that makes your eyes slightly red.
Note: this article is informational and is not medical advice; patients should consult an ophthalmologist or optometrist before starting or stopping any eye medication.
Frequently Asked Questions
What is Ryzumvi and what does the FDA approve it for?
Ryzumvi is phentolamine ophthalmic solution 0.75 percent, already approved for reversing exam-induced dilation, and on October 16, 2026 the FDA additionally approved it to treat presbyopia, age-related near vision loss, in adults.
How effective are the Ryzumvi eye drops for near vision?
The phase 3 VEGA-2 and VEGA-3 trials met primary and all key secondary endpoints with no treatment-related serious adverse events; effects are temporary and designed for on-demand near-vision improvement.
What are the side effects of Ryzumvi?
The most common in presbyopia studies were conjunctival hyperemia at 21 percent and application-site irritation at 16 percent, mostly mild and transient, and it is not recommended with active eye inflammation.
When can patients get Ryzumvi for presbyopia?
Viatris holds U.S. commercial rights and is arranging commercialization; pricing and launch timing have not been announced.
Sources:
